Biotec Services appoints Martin Lamb as Commercial Director

He has more than 20 years of industry experience

Biotec Services International, a supplier of temperature-controlled clinical trial services, has appointed Martin Lamb as Commercial Director.

Strengthening Biotec Services’ executive team, Lamb will lead the commercial department which is responsible for business development, project management and marketing.

Prior to joining Biotec Services, Lamb was Global Vice President of Business Development at Almac Clinical Services where he had direct responsibility for all business development, sales and marketing initiatives in support of Almac’s EU and US businesses.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

The challenges of controlled drugs supply

Controlled drugs present clinical supply challenges that only specialist suppliers are adept at handling. Rachel Griffiths, Associate Director, Biotec (a PCI company), explains why
Packaging

Packaging Coordinators Inc buys Biotec

Expands clinical trial and temperature-controlled pharma services with addition of Bridgend, Wales company
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Clinical supply chain for biosimilar studies

Comparative testing to demonstrate efficacy is mandatory for biosimilars, but time to market is key to commercial success. Martin Lamb, Biotec Services, examines areas where supply chain design and management can help reduce the risk of delays in such studies
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Subscribe now